DISEASE/TRAIT	frequency
Lung cancer	182
Colorectal cancer	177
Breast cancer	1116
Prostate cancer	284
Urinary bladder cancer	7
Thyroid cancer	22
Testicular cancer	3
Pancreatic cancer	69
Ovarian cancer	28
Bladder cancer	32
Esophageal cancer	13
Non-small cell lung cancer	17
Gastric cancer	14
Response to gemcitabine in pancreatic cancer	5
Esophageal cancer and gastric cancer	4
Erectile dysfunction and prostate cancer treatment	23
Breast cancer in BRCA2 mutation carriers	1
Non-small cell lung cancer (survival)	6
Small-cell lung cancer (survival)	1
"Thyroid cancer (Papillary, radiation-related)"	1
Response to tamoxifen in breast cancer	1
Breast cancer (survival)	9
Gallbladder cancer	7
Response to irinotecan in non-small-cell lung cancer	2
Lung cancer (asbestos exposure interaction)	2
Oral cavity and pharyngeal cancer	10
Endometrial cancer	23
Response to platinum-based chemotherapy in non-small-cell lung cancer	6
Testicular germ cell cancer	6
Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer	7
Estradiol plasma levels (breast cancer)	18
Non-melanoma skin cancer	4
Cervical cancer	34
Esophageal cancer  (alcohol interaction)	4
Lung Cancer (DNA repair capacity)	2
"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)"	7
Adverse response to chemotherapy in breast cancer (alopecia)	3
Lobular breast cancer (menopausal hormone therapy interaction)	2
Breast cancer (menopausal hormone therapy interaction)	2
Ovarian cancer in BRCA1 mutation carriers	11
Breast Cancer in BRCA1 mutation carriers	6
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)	3
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)	8
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)	5
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)	4
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)	7
"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)"	5
Breast cancer (early onset)	18
Lung cancer (smoking interaction)	2
Non-small cell lung cancer (recurrence rate)	2
Colorectal cancer (diet interaction)	13
Bladder cancer (smoking interaction)	5
Prostate cancer (early onset)	9
Response to radiotherapy in cancer (late toxicity)	10
Esophageal squamous cell cancer (length of survival)	1
Esophageal cancer (squamous cell)	7
Breast cancer (male)	3
Breast cancer (prognosis)	5
Urinary symptoms in response to radiotherapy in prostate cancer	1
Response to radiotherapy in prostate cancer (toxicity)	1
Epithelial ovarian cancer	50
Response to chemotherapy in breast cancer (hypertension) (bevacizumab)	3
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab)	13
Colorectal cancer (calcium intake interaction)	3
Colorectal cancer (aspirin and/or NSAID use interaction)	2
Platinum-induced myelosuppression in non-small cell lung cancer	1
Disease-free survival in breast cancer	2
Survival in rectal cancer	18
Survival in colon cancer	12
Survival in microsatellite instability low/stable colorectal cancer	12
Survival in endocrine treated breast cancer (estrogen-receptor positive)	1
Prostate cancer aggressiveness	3
Obesity in adult survivors of childhood cancer exposed to cranial radiation	4
Obesity in adult survivors of childhood cancer not exposed to cranial radiation	1
Cardia gastric cancer	1
Non-cardia gastric cancer	8
Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab)	3
Anthracycline-induced cardiotoxicity in childhood cancer	2
Survival in colorectal cancer	1
Survival in colorectal cancer (non-distant metastatic)	1
Colorectal cancer (oestrogen-progestogen hormone therapy interaction)	1
Progression free survival in metastatic colorectal cancer (chemotherapy interaction)	1
Response to carboplatin in ovarian cancer (MTT IC50)	2
Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50)	2
Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50)	3
Response to paclitaxel in ovarian cancer (MTT IC50)	1
Response to paclitaxel in ovarian cancer (Caspase 3/7 EC50)	2
Response to Pazopanib in cancer (hepatotoxicity)	1
Colorectal or endometrial cancer	29
Survival in colorectal cancer (distant metastatic)	4
Prostate cancer (survival)	4
Colorectal cancer (SNP x SNP interaction)	7
Prostate cancer (SNP x SNP interaction)	51
"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)"	11
"Response to radiotherapy in prostate cancer (toxicity, decreased urine stream)"	8
"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)"	6
Oropharynx cancer	17
Cancer	17
Cancer (pleiotropy)	26
Breast cancer (estrogen-receptor negative)	27
Response to radiotherapy in prostate cancer (overall toxicity)	16
Breast cancer (estrogen-receptor positive)	1
Colorectal cancer (alcohol consumption interaction)	2
Breast cancer-free interval (treatment with aromatase inhibitor)	1
Estrogen receptor status in breast cancer	1
Estrogen receptor status in HER2 negative breast cancer	1
Oral cavity cancer	9
Survival in head and neck cancer	1
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer	12
Colon cancer	2
Multiple keratinocyte cancers	17
HER2 status in breast cancer	1
Body mass index (change over time) in cancer	1
Body mass index (change over time) in lung cancer	3
Body mass index (change over time) in gastrointestinal cancer	3
Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease	4
Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease	5
Body mass index (change over time) in cancer or chronic obstructive pulmonary disease	3
Response to platinum-based neoadjuvant chemotherapy in cervical cancer	3
Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer	2
Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer	1
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer	14
Plasma estrone levels in resected estrogen-receptor positive breast cancer	2
Plasma androstenedione levels in resected early stage-receptor positive breast cancer	5
Survival in pancreatic cancer	61
Ovarian clear cell cancer	2
Endometrioid ovarian cancer	1
Low-grade serous ovarian cancer	1
Ovarian cancer in BRCA2 mutation carriers	2
Serous invasive ovarian cancer	21
Serous borderline ovarian cancer	10
High-grade serous ovarian cancer	21
Invasive epithelial ovarian cancer	19
Low-grade serous and serous borderline ovarian cancer	12
Lung cancer in ever smokers	111
Differentiated thyroid cancer	10
Papillary thyroid cancer	9
Lung cancer in never smokers	23
Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer	6
Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin	10
Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel	4
